ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On ...

ImmunityBio Chief Executive Officer Richard Adcock acknowledges the frustration with how long it’s taken getting the Dunkirk ...

ImmunityBio (IBRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

CEO Richard Adcock said the long-delayed Dunkirk manufacturing site is now “all systems go” after a unanimous resolution at a CCIDA board meeting. ・The Dunkirk facility is expected to serve as a key U ...

Is IBRX a good stock to buy? We came across a bullish thesis on ImmunityBio, Inc. on Investment Ideas by Antonio’s Substack ...

We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. ImmunityBio, Inc. is one of the best ...

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...

Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ...

The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of ----10(b) and 20(a) of the Securities Exchange ...

The stalled Dunkirk pharmaceutical project is moving ahead with a new lease for ImmunityBio and tighter controls.